SCHEMBL2113163

SCHEMBL2113163

C1=CCC2CNCC2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20748212 1.00
SCHEMBL1425396 1.00
SCHEMBL12620801 0.84 CCR5 (0.38)
SCHEMBL4871844 0.80 CCR5 (0.33)
SCHEMBL4531955 0.79
SCHEMBL2244194 0.79
SCHEMBL418167 0.74
SCHEMBL14096697 0.74
SCHEMBL416052 0.74
SCHEMBL260537 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167421-A1 Pyrimidine derivatives and use thereof as agricultural and horticultural fungicides ITO MASHITO 2007-07-19 US claimed
US-12545636-B2 Acyclic lipids and methods of use thereof RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2026-02-10 US disclosed
WO-2025052278-A1 PYRROLIDINE BASED CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS GENEVANT SCIENCES GMBH (CH) 2025-03-13 WO disclosed
WO-2025049419-A1 PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS GENZYME CORPORATION (US) 2025-03-06 WO disclosed
US-12161624-B2 Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B NOVARTIS AG (CH) 2024-12-10 US disclosed
US-12134602-B2 (−)-huperzine A processes and related compositions and methods of treatment YALE UNIVERSITY (US) 2024-11-05 US disclosed
EP-4402123-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF Renagade Therapeutics Management Inc. (US) 2024-07-24 EP disclosed
US-20240182412-A1 CYCLIC LIPIDS AND METHODS OF USE THEREOF RENAGADE THERAPEUTICS MAN INC (US) 2024-06-06 US disclosed
WO-2024028795-A1 HETEROBICYCLIC COMPOUNDS AS ORAL GLP1R AGONISTS ZYDUS LIFESCIENCES LIMITED (IN) 2024-02-08 WO disclosed
US-11773061-B2 Cyclic lipids and methods of use thereof RENAGADE THERAPEUTICS MANAGEMENT INC. (US) 2023-10-03 US disclosed
US-5457104-A Antibacterials BAYER AKTIENGESELLSCHAFT (DE) 1995-10-10 US disclosed
US-5409929-A Treating psychosis, dyskinesia THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1995-04-25 US disclosed
EP-0607825-A1 6-H-4-OXO-3-quinoline-carboxylic acids and their analogues as antibacterial agents BAYER AG (DE) 1994-07-27 EP disclosed
WO-1993016047-A1 HYDROISOINDOLINES AND HYDROISOQUINOLINES AS PSYCHOTROPIC DRUGS THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-08-19 WO disclosed
US-5216018-A Antidyskinetic agents DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-06-01 US disclosed
US-5202335-A Hypoglycemic, antidiabetic agents KISSEI PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 US disclosed
EP-0523512-A1 8-vinyl- and 8-ethinyl-quinolone carboxylic acids BAYER AG (DE) 1993-01-20 EP disclosed
EP-0520240-A1 7-Isoindolinyl-quinolone and naphthyridonecarboxylic acid derivatives BAYER AG (DE) 1992-12-30 EP disclosed
EP-0507534-A1 Succinic acid compounds KISSEI PHARMACEUTICAL CO., LTD. (JP) 1992-10-07 EP disclosed
EP-0056144-A1 Carboxylic acid derivatives, their preparation and use as pharmaceuticals Dr. Karl Thomae GmbH (DE) 1982-07-21 EP disclosed